


In the claims:

1. (Original) A compound represented by the following formula:




wherein R represents an unsubstituted pyridyl, furyl, or thienyl group,

m represents an integer of 1 to 3,

G represents a β -D-glucopyranosyl group, and the positions of substitution of the hydroxyl groups on the indolopyrrolo[1,2-a]carbazole ring are the 1- and 11-positions, or the 2- and 10-positions, or a pharmaceutically acceptable salt thereof.

2. (Original) The compound according to Claim 1, represented by the following formula:




wherein R and G are the same as defined in Claim 1,

or a pharmaceutically acceptable salt thereof.

3. (Original) The compound according to Claim 2, wherein R is a pyridine-4-yl group, or a pharmaceutically acceptable salt thereof.

4. (Original) The compound according to Claim 1, represented by the following formula:



wherein R and G are the same as defined in Claim 1,
or a pharmaceutically acceptable salt thereof.

5. (Original) An anti-tumor agent comprising, together with a pharmaceutically acceptable carrier or diluent, an effective amount of the compound according to Claim 1 or a pharmaceutically acceptable salt thereof, sufficient to exhibit antitumor activity

6. (Original) The anti-tumor agent according to Claim 5 which is used for the treatment of lung cancer.

7. (New) A method of treating cancer in a mammal in need of such treatment which comprises administering to the mammal an effective amount of the anti-tumor agent according to Claim 5, wherein the cancer is selected from: head and neck cancer, thyroid cancer, lung cancer, esophageal cancer, stomach cancer, hepatic cancer, pancreatic cancer, colon cancer, renal carcinoma, prostatic cancer, testis cancer, uterus cancer, ovarian cancer, breast cancer, brain tumor, leukemia, lymphoma, myeloma and stomach cancer